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Aluminum removal by hemodialysis. Aluminum kinetics were
studied in 24 patients on chronic hemodialysis. All patients had
elevated predialytic serum concentrations of aluminum (mean,
3.44 moles/liter), which correlated significantly with the inges-
tion of aluminum hydroxide (P < 0.01). Simultaneous measure-
ments of aluminum in plasma and ultrafiltrate revealed an
ultrafiltrability of about 20% of total plasma aluminum, thus
suggesting that 80% of aluminum is protein bound. When a
dialysate with a very low aluminum content (varying from 0.1 to
0.3 moles/liter) was used, mean values across the dialyzer were
3.20 and 2.67 moles/liter, respectively, showing a significant
decrease of plasma aluminum during dialyzer passage (P <
0.0001). It could be shown that dialysance of aluminum depends
on the concentration gradient between the free diffusible plasma
aluminum and the dialysate aluminum concentration. After 6
hours of dialysis, plasma aluminum concentrations were signifi-
cantly lower than were predialysis values (P < 0.0001). We
conclude that a negative aluminum balance during hemodialysis
can be assumed as long as the aluminum concentration of free
diffusible plasma aluminum lies above the aluminum concentra-
tion of the dialysate.
Soustraction d'aluminium par hémodialyse. La cinétique de
l'aluminium a été étudiée chez 24 malades en hemodialyse
chronique. Tous les malades avaient des concentrations sériques
élevées d'aluminium avant Ia dialyse (moyenne, 4,44 imoles/
litre) qui étaient significativement corrélées avec l'ingestion
d'hydroxide d'aluminium (P < 0,01). Des mesures simultanées
de la concentration d'aluminium dans le plasma et l'ultrafiltrat
ont montré une ultrafiltration d'environ 20% de l'aluminium
plasmatique total, ce qui suggère que 80% de l'aluminium est lie
aux protéines. Au moyen d'un dialysat très pauvre en aluminium
(de 0,1 a 0,3 moles/litre) les valeurs moyennes de part et d'autre
du dialyseur étaient de 3,20 et 2,67 .moles/litre respectivement,
ce qui indique une diminution significative de l'aluminium plas-
matique au cours du passage dans le dialyseur (P < 0,0001). Il a
pu être montré que Ia dialysance de l'aluminium depend du
gradient de concentration entre l'aluminium librement diffusible
du plasma et Ia concentration d'aluminium du dialysat. Après 6
heures de dialyse les concentrations plasmatiques d'aluminium
étaient significativement inférieures aux valeurs avant dialyse (P
< 0,0001). Nous concluons qu'un bilan negatif d'aluminium au
cours de l'hémodialyse peut être postulé aussi longtemps que Ia
concentration d'aluminium diffusible du plasma est superieure a
la concentration d'aluminium du dialysat.
Hyperaluminernia and high tissue burdens of alu-
minum are frequently found in patients on chronic
intermittent hemodialysis [1, 2]. It is suggested that
aluminum produces chronic toxicity and that dialy-
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sis dementia [21 and nonhypophosphatemic osteo-
malacic dialysis osteodystrophy [3] are manifesta-
tions of this aluminum intoxication.
Aluminum loading in hemodialysis patients may
be caused either by gastrointestinal absorption of
aluminum from aluminum-containing antacids or by
aluminum transfer from dialysate during hemodialy-
sis. The aluminum kinetics during hemodialysis are
still an issue of controversy. Kaehny et al [41 find a
positive aluminum balance during each hemodialy-
sis if the dialysate contains virtually any aluminum,
and they discount the possibility of aluminum re-
moval during dialysis because of high protein bind-
ing of aluminum in plasma. In contrast to this, the
same group finds an ultrafiltrable fraction of plasma
aluminum of about 50% in dogs [5] and a significant
increase in urinary aluminum excretion during oral
aluminum loading in normal man [61. Considerable
amounts of aluminum have been found in the ultra-
filtrate of normal man [7] as well as in patients with
uremia [8]. These findings would theoretically sug-
gest the possibility of aluminum removal during
hemodialysis if a low enough dialysate aluminum
concentration is used. Although Arieff et al [9] have
cast some doubt about a direct toxicity of aluminum
for the various diseases with disturbed blood brain
barriers and high brain aluminum concentrations,
we wanted to study the aluminum kinetics during
hemodialysis with a dialysate containing a very low
concentration of aluminum.
Methods
We studied 24 patients (10 females, 14 males)
aged from 18 to 54 years and under chronic hemo-
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dialysis therapy from 1 to 96 months (27.9 [sDI
25.7). Eight patients had been bilaterally nephrecto-
mized, and the remaining 16 were functionally
anephric (glomerular filtrate of less than 3 mI/mm).
Hemodialysis was performed three times weekly,
for 6 hours each time, with hollow-fiber capillary
kidneys (C-DAK, Cordis Dow) that had a
membrane surface of 1.8 or 2.5 m2.
All patients had received aluminum hydroxide as
a phosphate binder. At the time of the study, the
daily amount of aluminum hydroxide ingestion
ranged from 0 to 14.4 g (4.67 4.5). The individual
patient's dosage had not been changed since at least
4 weeks prior to the study. All examinations were
done after an overnight fast. Twenty healthy volun-
teers (10 females and 10 males from medical staff)
served as controls for serum aluminum concentra-
tions.
Before dialysis was started, blood from all pa-
tients was drawn from the arteriovenous fistula into
plastic tubes. These samples were then centrifuged
at room temperature after clotting, transferred to
another plastic tube, stored at 40 C, and analyzed
within 24 hours. During hemodialysis, plasma sam-
ples were obtained from the blood inflow and blood
outflow lines of the dialyzer. Minimal transmem-
brane pressure was applied to avoid ultrafiltration.
At the end of dialysis, blood was drawn from the
blood inflow line. All plasma samples were handled
in the same manner as the serum samples. Serum
and plasma aluminum measurements gave identical
results in 10 patients tested (r = 0.98).
Ultrafiltrate was obtained by disconnecting the
dialysate supply from the dialyzer and applying a
negative pressure of 200 mm Hg by a suction pump.
Application of pressure began 5 mm after hemodial-
ysis was started, and it was terminated when 50 ml
of ultrafiltrate were obtained. The remaining dialy-
sate and the first 30 ml of ultrafiltrate were dis-
charged. Dialysate was obtained from the dialysate
inflow site.
Measurements of aluminum were performed by
flameless atomic absorption spectrophotometry by
the method of Fuchs et al [101. A Perkin Elmer 300
atomic absorption spectrophotometer, equipped
with a graphite duvette (HGA 74) and an aluminum
hollow-cathode lamp (309 nm and 25 mAmps) with
Deuterium background compensation was used.
The program consisted of the following: dry cycle
(step 1, 30 sec at 60° C; step 2, 25 sec at 140° C),
char cycle (step 1, 15 sec, increasing to 1350° C;
step 2, 10 see, 1380° C), and atomize cycle (10 see,
2700° C).
During the atomize cycle, the argon gas purge
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Fig. 1. Extinctions of atomic absorption spectrophotometry of a
2.22-pmolesIliter aluminum standard at various phosphate con-
centrations.
(1.5 ml/min) was stopped to allow more sensitive
measurements. Ten microliters of each sample were
injected directly into the graphite tube with an
Eppendorf pipette. Analysis was done in triplicate,
and for each measurement a new graphite cuvette
was used. The coefficient of variation with this
method was below 3%, and the detection limit was
0.1 pmole s/liter.
Because phosphate in high concentrations has
been found to interfere with the aluminum atomic
absorption response [11], the influence of phos-
phate at concentrations found in the plasma of
hemodialysis patients was tested. To a standard
solution containing 2.22 pmo1es/liter aluminum,
varying doses of sodium orthophosphate were add-
ed, resulting in phosphate concentrations from 0.55
to 8.80 mg/dl. As can be seen from Fig. 1, the
various phosphate concentrations did not influence
the extinctions of the aluminum standard solution.
The predialytic plasma phosphate concentrations in
our patients ranged from 4 to 6 mg/dl, and the
postdialysis values were between 2 and 4 mg/dl.
Immunoreactive parathyroid hormone (iPTH)
was measured by a radioimmunoassay technique
that uses an antibody against the C-terminal part of
the PTH molecule [121. The normal range with this
method is from 1.8 to 4.5 mU/mI.
Statistical analysis was performed with Student's
t test for paired data and linear regression analysis,
where appropriate. A 95% confidence limit (P <
0.05) was used.
Results
Predialytic serum aluminum concentrations. In
all patients the serum aluminum concentrations
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Fig. 2. Correlation between serum aluminum levels and the
amount of daily ingested aluminum hydroxide.
6
5
,- .
.5
.
.
.
.I
• •S •
.5
E
S y 3.095 + 0.01 2xr 0.302
P= NS
Fig. 4. Correlation between serum aluminum and serum iPTH
levels.
5
.5
.50
SS. xxx
5 mm after End of HP
start of HD
Fig. 5. Behavior of plasma aluminum during hemodialysis (HD).
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Fig. 3. Correlation between serum aluminum concentration and
duration of dialysis therapy.
were elevated before the beginning of hemodialysis.
The values ranged from 1.82 to 5.92 llmoles/liter
(3.44 1.05), whereas the serum aluminum in the
control group ranged from 0.7 to 1.2 pmoJes/liter
(0.92 0.14). A significant correlation between the
concentration of serum aluminum and the amount
of daily ingested aluminum hydroxide was found
(Fig. 2). There was, however, no such correlation
between serum aluminum and the duration of dialy-
sis therapy or serum PTH levels (Figs. 3 and 4).
Plasma aluminum concentration during hemo-
dialysis. The plasma aluminum concentration de-
creased significantly during dialyzer passage, thus
showing a significant difference between aluminum
concentration of dialyzer blood inflow versus dia-
lyzer blood outflow site (Fig. 5, Table 1). Plasma
aluminum at the end of dialysis was significantly
reduced when compared with the aluminum con-
centration at the beginning (Fig. 5, Table I).
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Table 1. Aluminum concentrations of plasma at the dialyzer blood inflow (AlbI) and blood outflow (Albo) site 5 mm after start of
hemodialysis (HD); the aluminum content of the ultrafiltrate (A1UF) and the aluminum content of plasma at the blood inflow site after
6 hours of dialysis; and the ultrafiltrable fraction of total plasma aluminum
5 Minutes after start of HD End of HD
Aluminum in the ultrafiltrate. A considerable
amount of aluminum was found in the ultrafiltrate,
with concentrations ranging from 0.37 to 1.07
p.moles/liter (0.66 0.25). The ultrafiltrable frac-
tion of plasma aluminum, that is, the percentage of
the aluminum concentration in the ultrafiltrate from
the total plasma aluminum concentration, was
found to be consistently about 20% (Table 1).
Aluminum in dialysate. Aluminum concentra-
tions of dialysate at the dialysate inflow site were
repeatedly measured and were always between 0.1
and 0.3 pmoles/1iter.
Discussion
Great attention has been paid to the aluminum
concentration of the dialysate as being an important
source of aluminum-loading in patients on chronic
hemodialysis [3, 13—181, and it was believed that
aluminum cannot be removed from plasma by he-
modialysis [4, 191. Our results show a significant
difference in plasma aluminum concentrations be-
tween dialyzer blood inflow and blood outflow sites
and a significant decrease of plasma aluminum
concentrations after 6 hours of hemodialysis. The
aluminum content of in-vivo-obtained ultrafiltrate
taken as a parameter for free diffusible aluminum
was consistently 20% of the total plasma aluminum,
indicating that about 80% of plasma aluminum is
protein bound. Because of the after-dissociation,
the in vitro estimation of protein-bound aluminum
by means of in vitro ultrafiltrability as reported by
Lundin et a! [7] might result in a higher value of
nonprotein-bound aluminum. Kovaichik et al [5]
calculated protein binding from clearance studies in
experimental animals and found the aluminum
clearance to be 50% of the inulin clearance. They
concluded from that a protein binding of 50%. This
conclusion can only be correct if aluminum is
neither secreted nor reabsorbed by the tubule,
which, as far as we know, is obscure. So the
findings of 40% and 50%, respectively, of ultrafiltra-
ble aluminum may not reflect the true in vitro
situation of protein binding.
The aluminum passage through a given dialysis
membrane is determined by the concentration-gra-
dient driving force. The appropriate concentration
gradient is that between dialysate aluminum con-
centration and the concentration of freely diffusible,
Alb Alb0 AIUF AlbI
p.molesl!iter j.mo/esl/iter Ultraffitrable fraction
%
1.36 1.23 0.39 0.88 28.6
1.38 0.98 0.38 0.74 27.5
1.40 0.89 0.42 0.72 30.0
1.44 0.98 0.44 0.85 30.5
1.75 1.13 0.48 0.83 27.4
2.12 1.64 0.42 1.26 19.8
2.26 1.89 0.45 1.28 19.9
2.40 1.88 0.42 0.88 17.5
2.49 1.69 0.38 0.99 15.2
2.84 1.99 0.82 1.12 28.8
2.96 2.45 0.82 1.52 27.7
3.14 2.88 0.37 2.12 11.7
3.14 2.75 0.91 1.70 28.9
3.36 2.92 0.58 2.13 17.2
3.48 2.62 1.04 1.59 29.8
3.76 3.37 0.56 2.50 14.8
3.84 3.17 0.97 2.76 25.2
3.99 3.75 0.53 3.15 13.2
3.99 3.38 0.99 2.83 24.8
4.42 4.03 0.78 3.67 17.6
4.86 4.17 0.71 3.78 14.6
5.28 4.59 1.02 4.45 19.3
5.52 4.76 1.07 4.12 10.3
5.62 4.98 0.98 4.53 17.4
Mean 3.20 2.67 0.66 2.10 21.8
si 1.32 1.27 0.25 1.27 7.9
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nonprotein bound, plasma aluminum. Our mea-
sured arteriovenous difference (that is, the differ-
ence of the aluminum content in dialyzer blood inlet
and blood outlet) in plasma aluminum was always in
accordance with the theoretically expected 'appro-
priate concentration gradient." The aluminum ki-
netics can be expressed by the following equation:
Albj — Albo = ALUF — ALD
where Albj and Albo are the aluminum concentra-
tions of blood inlet and blood outlet of the dialyzer
respectively, Alr]F is the ultrafiltrable fraction of
plasma aluminum, and AID is the aluminum content
of the dialysate. This shows that during blood
passage through the dialyzer the decrease in plasma
aluminum corresponds to the concentration gradi-
ent between the free diffusible parts of aluminum in
plasma and dialysate. As the aluminum concentra-
tion of our dialysate was always lower than ultrafil-
trable plasma aluminum, a negative aluminum bal-
ance during dialysis can be assumed.
Because there is no aluminum loading during the
dialysis in our patients, it can be assumed that the
major source of the observed hyperaluminemia is
probably enhanced gastrointestinal absorption of
aluminum, which is also indicated by the finding of
a significant positive correlation between the
amount of daily ingested aluminum hydroxide and
serum aluminum. This is in accordance with the
finding of an increase in serum aluminum concen-
trations after oral administration of aluminum com-
pounds in patients with uremia [1, 6, 21, 221.
The flat slope of the regression line correlating
serum aluminum and daily aluminum hydroxide
intake, however, suggests that there are other fac-
tors influencing serum aluminum concentrations.
Besides distribution and redistribution of aluminum
from tissue to blood and aluminum loading or
removal during hemodialysis, individual variations
in gastrointestinal absorption may operate.
The lack of a correlation between the serum
aluminum concentration and the duration of dialysis
therapy seems to reflect the situation in our dialysis
unit where most of the gastrointestinal-absorbed
aluminum is removed during each hemodialysis
session.
Mayor, Keiser, and Pao [231 were able to demon-
strate that parathyroid extract increases the absorp-
tion of aluminum in rats and found a positive
correlation between serum aluminum and serum
PTH in dialysis patients. In accordance with the
finding of Aifrey et al [24], no correlation between
serum PTH and serum aluminum concentrations
was found in our patients, and a role of PTH in
aluminum metabolism cannot be supported by our
findings.
Reprint requests to Dr. H. Graf. Second Medical Department,
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